No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Bioeq AG and Bio Usawa Partner to Commercialise Ranibizumab Biosimilar in Africa
On 1 July 2025, Formycon announced that Bioeq AG, which holds the exclusive worldwide commercialisation rights for Formycon’s FYB201, biosimilar to Genentech’s Lucentis® (ranibizumab)…